{"id":"W4405045423","doi":"10.1182/blood-2024-194827","title":"Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":39,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Internal medicine; Phases of clinical research; Tolerability; Leukemia; Oncology; Refractory (planetary science); Acute leukemia; Gastroenterology; Adverse effect; Clinical trial; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002125832,0.0002046129,0.000211259,0.000121204,0.00006794996,0.00002860195,0.0002445994,0.0001321225,0.00001513012],"category_scores_gemma":[0.00009424713,0.0001311905,0.00005639554,0.0003663753,0.00006435072,0.00001656382,0.000114753,0.000224155,0.000002517014],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000633243,"about_ca_system_score_gemma":0.0001757818,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008781417,"about_ca_topic_score_gemma":0.0005805635,"domain_scores_codex":[0.9984345,0.0001076759,0.0004976989,0.000464283,0.0002718389,0.0002240342],"domain_scores_gemma":[0.9992068,0.00002020057,0.0001393397,0.0005146342,0.00006051833,0.00005847556],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.01718872,0.06933136,0.02504459,0.0002818515,0.001273934,0.0004236937,0.005110715,0.00005648741,0.8571445,0.00004258021,0.01835987,0.005741629],"study_design_scores_gemma":[0.1240386,0.02309881,0.004026523,0.0004811267,0.000225136,0.000005526711,0.000643311,0.00003814961,0.8256279,0.00001189459,0.0212516,0.0005513942],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9982337,0.000166303,0.000003214287,0.0000555131,0.0001633864,0.0009113068,0.0002055283,0.00001493878,0.0002460861],"genre_scores_gemma":[0.9985448,0.00001924183,0.00003835053,0.00004365744,0.0001013593,0.00008331642,0.0001837994,0.00003053058,0.000954922],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1068499,"threshold_uncertainty_score":0.5349793,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008586955842984497,"score_gpt":0.2690134804382673,"score_spread":0.2604265245952828,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}